All In Biotech

Drug Trial Radar · NCT06704009

NT-101 Topical Ophthalmic Solution in Patients With Wet AMD

A Randomized, Open-Label, Parallel-group, Multicenter Phase 1/2 Study to Evaluate the Safety and Exploratory Efficacy of NT-101 Topical Ophthalmic Solution in Patients With Wet Age-Related Macular Degeneration (AMD)

Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Mar 11, 2025

Primary completion

Dec 15, 2025

Study completion May 6, 2026

Sponsor

Lead sponsor
NexThera Co., Ltd.Industry
Sponsor type
Industry
Collaborators
KCRN Research, LLC
First posted
Nov 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1/2 Trial NT-101 Topical Ophthalmic Solution in Patients with Wet Age-Related Macular Degeneration (AMD)

Conditions

  • Wet Age Related Macular Degeneration
  • Wet AMD

Interventions

  • NT-101 Low DoseDrug

    Low concentration of NT-101 (0.05 mM)

  • NT-101 High DoseDrug

    High concentration of NT-101 (0.2 mM)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and Severity of Treatment-Emergent Adverse Events (TEAEs) up to Week 8Time frame: 8 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Elman Retina Group

    Rosedale, Maryland

  • Duke Eye Center

    Durham, North Carolina

  • Erie Retina Research

    Erie, Pennsylvania

  • Texas Retina Associates

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.